香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 山東威高集團醫用高分子製品股份有限公 司 Shandong Weigao Group Medical Polymer Company Limited * （在中華人民共和國註冊成立的股份有限公司） （股份代號：1066） (1)建議修訂公司章程 及 (2)建議實行H股全流通 本公佈乃由本公司根據上市規則第13.09(2)(a)條及第13.51(1)條及證券及期貨 條例（香港法例第571章）第XIVA部內幕消息條文（定義見上市規則）作出。 建議修訂公司章程 董事會建議修訂公司章程，以（其中包括）(i)令現有公司章程符合自二零二四 年七月一日起生效的公司法及中國證監會於二零二五年三月二十八日發佈的 《上市公司章程指引》等相關法律、法規、規章和規範性文件的規定；(ii)鑒於 二零二四年六月十一日生效的有關庫存股份的上市規則修訂，令本公司可靈 活購買或收購股份作為庫存股份持有；(iii)配合近期上市規則有關進 ...

威高股份(01066)发布公告，燕霞因个人发展需求，已提出辞任公司董事会副主席及非执行董事，自 2025年10月8日起生效。辞任生效后，燕霞将不再担任公司任何职务。 ...

智通财经APP讯，威高股份(01066)发布公告，燕霞因个人发展需求，已提出辞任公司董事会副主席及非 执行董事，自2025年10月8日起生效。辞任生效后，燕霞将不再担任公司任何职务。 ...

格隆汇9月29日丨威高股份(01066.HK)发布公告，燕霞因个人发展需求，已提出辞任公司董事会副主席 及非执行董事，自2025年10月8日起生效。辞任生效后，燕女士将不再担任公司任何职务。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 燕女士確認，彼與董事會之間並無意見分歧，亦無有關彼辭任的事宜須提請本公司證 券持有人或香港聯合交易所有限公司垂注。 燕女士的辭任不會導致現有董事會成員人數低於法定最低人數，不會影響本公司董事 會的正常運作，亦不會影響本公司現有業務的正常運行。 董事會謹藉此機會對燕女士於其任期內對本公司的寶貴貢獻表示感謝。 承董事會命 山東威高集團醫用高分子製品股份有限公司 董事辭任 山東威高集團醫用高分子製品股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，燕霞女士(（「燕女士」）因個人發展需求，已提出辭任本公司董事會副主席及非執 行董事，自二零二五年十月八日起生效。辭任生效後，燕女士將不再擔任本公司任何 職務。 二零二五年九月二十九日 中國山東省威海市 1 於本公佈刊發日期，董事會成員包括： 龍 經先生 （執行董事） * 僅供識別 2 叢日楠先生 （執行董事） 盧均強先生 （執行董事） 王道明先生 （執行董事 ...

SUMMARY For the six months ended 30 June 2025 (the "Period"), the unaudited revenue of Shandong Weigao Group Medical Polymer Company Limited (the "Company") and its subsidiaries (the "Group") was approximately RMB6,644,048,000 ( s a m e p e r i o d i n 20 2 4: a p p ro x i m a t e l y RMB6,635,688,000), representing an increase of approximately 0.1% as compared with the same period last year, the unaudited net profit attributable to the owners of the Company was approximately RMB1,008,317,000 (same period i ...

Core Viewpoint - Northeast Securities has given a "buy" rating to Weigao Group (01066) following its successful acquisition of MDSAP certification, which will facilitate the international expansion of its products [1] Group 1: Company Performance and Projections - The company is a leading provider of comprehensive medical system solutions in China, focusing on platformization, internationalization, and digitalization to maintain its market leadership [1] - Revenue projections for Weigao Group are estimated at 135.41 billion, 149.60 billion, and 163.01 billion yuan for the years 2025 to 2027, with net profits of 20.76 billion, 23.57 billion, and 26.05 billion yuan respectively, corresponding to PE ratios of 12X, 10X, and 9X [1] Group 2: MDSAP Certification and Product Development - The MDSAP certification is recognized by regulatory bodies in the US, Australia, Brazil, Canada, and Japan, allowing manufacturers to streamline their quality management system audits, thus saving time and resources [2] - The company plans to enhance its product matrix by transitioning from low-cost to high-cost/specialized products, with over 100 new products expected to be approved in the next three years [2] - The orthopedic segment will focus on new materials, regenerative rehabilitation, smart assistance, and 3D printing, particularly in minimally invasive spine and pain management [2] - The company is also expanding its blood management segment, with a projected production capacity of over 100 million blood bags by 2025 and an additional 20 million overseas capacity expected next year [2] Group 3: International Revenue and Acquisitions - In the first half of 2025, the company achieved overseas revenue of 16.24 billion yuan, a year-on-year increase of 3.98%, accounting for 24.44% of total revenue, with significant growth in the US and EMEA regions [3] - Recent acquisitions include Argon, a US interventional device manufacturer, GHC Healthcare, a medical device distributor, and Radsource, a blood irradiation device manufacturer, which have been integrated to enhance synergies [3]

Core Viewpoint - Weigao Co., Ltd. has successfully obtained the MDSAP certification, enhancing its international market expansion capabilities and solidifying its leading position in the medical system solutions sector [1][2]. Financial Projections - The company is projected to achieve revenues of 135.41 billion, 149.60 billion, and 163.01 billion CNY for the years 2025 to 2027, with corresponding net profits of 20.76 billion, 23.57 billion, and 26.05 billion CNY, resulting in PE ratios of 12X, 10X, and 9X respectively [1]. MDSAP Certification Impact - The MDSAP certification, recognized by regulatory bodies in the US, Australia, Brazil, Canada, and Japan, allows manufacturers to streamline their quality management system audits, significantly reducing time and resource costs associated with multiple country certifications [2]. Product Development and Market Strategy - The company is focusing on enhancing its product matrix by transitioning from low-cost to high-cost/specialized products, with plans to approve over 100 new products in the next three years [2]. - In the orthopedic sector, the company is expanding into new materials, regenerative rehabilitation, smart assistance, and 3D printing, particularly in minimally invasive spine and pain management areas [2]. - The interventional segment has plans to shift some main products to mainland production, with upcoming product launches and academic seminars for Cleaner Vac [2]. - The pharmaceutical packaging segment is developing new production lines for pre-filled syringes and automatic injection pens, expected to commence production in 2026 [2]. - The blood management segment anticipates exceeding a total production capacity of 100 million blood bags by 2025, with an additional 20 million sets of overseas capacity planned for next year [2]. International Revenue Performance - In the first half of 2025, the company reported overseas revenues of 16.24 billion CNY, a year-on-year increase of 3.98%, accounting for 24.44% of total revenue, with significant growth in the US and EMEA regions [3]. - The company has made strategic acquisitions in recent years, including Argon, GHC Healthcare, and Rad Source, to enhance its overseas platform integration and realize synergies [3].

Group 1 - The article reports on share buybacks conducted by various companies on September 19, 2025, with Tencent Holdings (00700) having the largest buyback amount of 551 million yuan for 857,000 shares [1][2] - Other notable companies involved in buybacks include Shankou Holdings (00412) with 3.7 million shares repurchased for 22.62 million yuan, and Tianli International Holdings (01773) with 3.41 million shares for 10.62 million yuan [2] - The total number of shares repurchased by Tencent Holdings in the year reached 59.863 million, accounting for 0.651% of its total share capital [2] Group 2 - Haier Smart Home (06690) repurchased 300,000 shares for 8.08 million yuan, representing 0.011% of its total share capital [2] - Other companies like Coolpad Group (02369) and Weigao Group (01066) also participated, with Coolpad repurchasing 1.092 million shares for 1.42 million yuan, and Weigao repurchasing 440,000 shares for 2.56 million yuan, accounting for 3.365% of its total share capital [2] - The buyback activities reflect a trend among companies to utilize excess cash for share repurchases, potentially signaling confidence in their future performance [1][2]

智通财经APP讯，威高股份(01066)发布公告，该公司于2025年9月19日斥资256.02万港元回购44万股股 份，每股回购价格为5.73-5.88港元。 ...